Evidence map›Paper›PMID 25396144›Full record

ArticleIndian dermatology online journal2014

Pentoxifylline and its applications in dermatology.

Iffat Hassan, Konchok Dorjay, Parvaiz Anwar

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian dermatology online journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07626788 (Efficacy and Safety of Pentoxifylline as Add-On Therapy for Mild-to-Moderate Plaque Psoriasis), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07626788 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Pentoxifylline as Add-On Therapy for Mild-to-Moderate Plaque Psoriasis: A Double-Blind Randomized Placebo-Controlled Trial

TypeinterventionalSponsorWasuchon ChaichanRan2026 to 2028Enrolled140ConditionsPsoriasisArmsPentoxifylline 400 mg Oral Tablet, Placebo
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Iffat HassanDepartment of Dermatology, STD and Leprosy, Government Medical College Srinagar, University of Kashmir, Jammu and Kashmir, India.
Konchok DorjayDepartment of Dermatology, STD and Leprosy, Government Medical College Srinagar, University of Kashmir, Jammu and Kashmir, India.
Parvaiz AnwarDepartment of Dermatology, STD and Leprosy, Government Medical College Srinagar, University of Kashmir, Jammu and Kashmir, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pentoxifylline is a methyl-xanthine derivative with many anti inflammatory effects. Pentoxifylline has been found to be effective for many dermatological as well as non-dermatological conditions. It has been used both as primary drug as well as adjuvant and is a safe and relatively cost-effective alternative drug. In this article, we review the literature and highlight various important aspects of pentoxifylline.

Indexed as

Cost effectivemethyl xanthinepentoxifyllinesafe

Identifiers

PMID25396144
PMCPMC4228656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.